胃肠道间质瘤的辅助治疗和新辅助治疗进展

Advances in Adjuvant and Neoadjuvant Therapy of Gastrointestinal Stromal Tumors

胃肠道间质瘤（GIST）是胃肠道最常见的间叶源性肿瘤,由于酪氨酸激酶抑制剂甲磺酸伊马替尼的成功应用.该病已成为实体瘤分子靶向治疗的经典模型.目前,GIST的治疗已由原先简单的手术切除发展为针对不同病情采取包括手术、辅助治疗和新辅助治疗在内的个体化治疗策略.本文对近年来GIST的辅助治疗和新辅助治疗进展作一综述.

Gastrointestinal stromal tumor （GIST） is the most common mesenchymal tumor in gastrointestinal tract, which has been a model of molecularly targeted therapy for solid tumors because of the successful use of tyrosine kinase inhibitor imatinib mesylate. At present, the management of GIST has updated from surgical resection to individualized treatment strategy, which includes surgical resection, adjuvant therapy and neoadjuvant therapy. The purpose of this article is to review the recent advances in adjuvant and neoadjuvant therapy of GIST.